Given the impressive 97% ORR and 78% CR in the Phase 1/2 study, how does AFM13 redefine treatment expectations for patients with heavily pretreated advanced-stage r/r PTCL?

What are the implications of the 9.8 months median EFS and 84% survival rate at 12 months for patients treated with AFM13, especially in the context of r/r PTCL's historically poor prognosis?

Can you elaborate on the significance of the good safety and tolerability profile of AFM13, particularly in the absence of CRS, GvHD, and ICANS, for patients with advanced-stage r/r PTCL?

How does AFM13's mechanism of action, as an innate cell engager targeting CD30, differ from existing therapies for r/r PTCL, and what advantages does it offer?

The study reports mild to moderate IRRs in only 7.7% of AFM13 infusions. How does this impact the overall management and quality of life for patients undergoing this treatment?

With the 72% CR rate assessed at 6 months and 30% of patients remaining in CR beyond 12 months, what potential does AFM13 hold for achieving long-term remission in r/r PTCL?

Given the study’s outcomes, how might AFM13 influence future research directions and treatment protocols in the field of r/r PTCL and other CD30-positive lymphomas?

Reflecting on the LuminICE-203 Phase 2 study, what are the anticipated advancements or areas of focus that could further establish AFM13 as a key therapy in r/r PTCL management?